The Real-World Value Assessment for Lifelong Universal Healthcare Security (hereinafter referred to as “R-VALUES”) is a key institutional innovation that enables China’s healthcare security system to move toward “value-oriented strategic purchasing”. This paper systematically elaborates on the practical background and strategic significance of R-VALUES, analyzing the historic achievements China’s healthcare security has made in terms of coverage scale, fund operation, and innovative drug coverage, as well as the emerging challenges posed by accelerated population aging, rapid iteration of medical technologies, and growing uncertainties in the clinical value of pharmaceutical products. On this basis, the paper defines the core evaluation framework of R-VALUES from three dimensions—relative value, long-term value, and systemic value—and systematically introduces its implementation pathways from four aspects: data infrastructure development, standard and specification formulation, organizational mechanism building, and application translation of assessment outcomes. On the basis of respecting internationally accepted norms, R-VALUES has established an evaluation system based on China's real-world data, and enriched the methodological toolbox for global pharmaceutical value assessment, offering a replicable practical approach for developing countries to implement strategic purchasing in healthcare security.
Key words
real-world value assessment for lifelong universal healthcare security /
strategic purchasing /
real-world data /
value dimensions /
healthcare governance
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 国家医疗保障局. 2025年全国医疗保障事业发展统计公报[EB/OL].(2026-07-16)[2026-07-30].https://www.nhsa.gov.cn/art/2026/7/16/art_7_21451.html.
[2] 新华社.5大关键词,看“十四五”期间医保答卷[EB/OL].(2025-07-25)[2026-07-27].https://www.gov.cn/zhengce/jiedu/tujie/202507/content_7033687.htm.
[3] 国家医疗保障局.积极进取担当作为全力推进医保高质量发展——全国医疗保障工作会议在京召开[EB/OL].(2025-12-13)[2026-07-27].https://www.nhsa.gov.cn/art/2025/12/13/art_14_19020.html.
[4] 国家医疗保障局.国家医保局“支持创新药高质量发展的若干措施”新闻发布会实录[EB/OL].(2025-07-01)[2026-07-27].https://www.nhsa.gov.cn/art/2025/7/1/art_14_17065.html.
[5] 王震,宋国旗,朱凤梅,等.医疗保障推动经济社会高质量发展:路径与成效[EB/OL].(2026-07-07)[2026-07-27].https://www.nhsa.gov.cn/art/2026/7/7/art_14_21325.html.
[6] 国家医疗保障局办公室.关于氢溴酸他泽司他片有关事项的通知:医保办函〔2026〕26号[EB/OL].(2026-03-09)[2026-07-27].https://www.nhsa.gov.cn/art/2026/3/9/art_109_19847.html.
[7] 民政部,全国老龄办.2024年度国家老龄事业发展公报[EB/OL].(2025-07-24)[2026-07-27].https://www.mca.gov.cn/n152/n165/c1662004999980006089/part/21508.pdf.
[8] 国家医疗保障局. 2024年全国医疗保障事业发展统计公报[EB/OL].(2025-07-14)[2026-07-27].https://www.nhsa.gov.cn/art/2025/7/14/art_7_17248.html.
[9] Ferrara R, Ricciuti B, Ambrogio C, et al.The anti-programmed cell death protein-1/programmed death-ligand 1 me-too drugs tsunami: hard to be millennials among baby boomers[J/OL].Journal of Thoracic Oncology,2023,18(1).
[10] Olivier T, Prasad V.The approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the FDA[J].Translational Oncology, 2022, 15(1): 101374.
[11] 赵蕾,王立,鲁梅花,等.唑来膦酸与阿仑膦酸钠治疗绝经后骨质疏松症的效果和安全性比较[J].中国综合临床,2017,33(12):4.
[12] Soria J C, Ohe Y, Vansteenkiste J, et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J].New England Journal of Medicine, 2018, 378(2): 113.
[13] Ramalingam S S, Vansteenkiste J, Planchard D, et al.Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC[J].New England Journal of Medicine, 2019, 382(1).
[14] Spira A I, Ran T, Lin I, et al.Risk factors associated with suboptimal real-world outcomes in patients with EGFR-mutated non-small cell lung cancer treated with front-line recommended therapy[J]. Advances in Therapy, 2025, 42(7).
[15] Sato Y, Sumikawa H, Shibaki R, et al.Drug-related pneumonitis induced by osimertinib as first-line treatment for epidermal growth factor receptor mutation-positive non-small cell lung cancer[J]. CHEST,2022,162(5):1188-1198.
[16] Prof L K B, Prof F A, Frederiksen M, et al. Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial[J].The Lancet Diabetes & Endocrinology, 2025,13(7): 556-567.
[17] 国家心血管病中心.中国心血管健康与疾病报告2024[R].2024.
[18] International Diabetes Federation. IDF diabetes atlas[EB/OL].(2026)[2026-07-29].https://diabetesatlas.org/.
[19] 刘喜恩,金松,唐建宇,等.基于大规模真实世界数据的人促红细胞生成素与罗沙司他治疗肾性贫血的比较性研究[J].中国医院用药评价与分析,2026(3):261-265.
[20] Finn R S, Martin M, Rugo H S, et al.Palbociclib and letrozole in advanced breast cancer[J].New England Journal of Medicine, 2016, 375(20).
[21] Slamon D J, Diéras V, Rugo H S, et al.Overall survival with palbociclib plus letrozole in advanced breast cancer[J/OL]. Journal of Clinical Oncology,2024,42(9).
[22] Goetz M P, Toi M, Huober J, et al.Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3[J/OL].Annals of Oncology,2024,35(8).
[23] Hortobagyi G N, Stemmer S M, Burris H A, et al.Overall survival with ribociclib plus letrozole in advanced breast cancer[J/OL].New England Journal of Medicine,2022,386(10).
[24] 钠-葡萄糖转运体2抑制剂在慢性肾脏病患者临床应用的中国专家共识(2023年版)专家组.钠-葡萄糖转运体2抑制剂在慢性肾脏病患者临床应用的中国专家共识(2023年版)[J].中华肾脏病杂志,2023,39(11):879-888.
[25] Mok T, Camidge D R, Gadgeel S M, et al.Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Annals of Oncology, 2020, 31(8):1056-1064.
[26] Nijs K D, Koning H J D, Aalst C V D, et al. Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012-2021)[J]. European Journal of Cancer, 2024, 208(000): 7.
[27] 龚海燕,赵苗苗,张华,等.县域内开展万人前列腺癌筛查的卫生经济学评价[J].江苏卫生事业管理,2025,36(8):1227-1230.
[28] 国家医保局办公室.关于发布真实世界医保综合价值评价国家可信评价点网络公约和成员名单的公告[EB/OL].(2026-01-16)[2026-07-29].https://www.nhsa.gov.cn/art/2026/1/16/art_109_19379.html.
[29] 国家医疗保障局办公室.关于开展真实世界医保综合价值评价试点工作的通知:医保办发〔2025〕15号[EB/OL].(2025-09-23)[2026-07-28].https://www.nhsa.gov.cn/art/2025/9/23/art_109_17984.html.
